StockData
Ocugen, Inc. logo

Ocugen, Inc. (OCGN) stock

OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$0.76−0.02 (-2.11%)

Close on Nov 17, 2026Market cap $256.60MP/E –Yield –

Ocugen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Ocugen's price to sales ratio was 84.3× on Jan 30, 2026, against 44.9× a year earlier. Over the last 4 years it ranged from 18.0× to 487.9×, with a median of 60.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 202684.3×+5.8
2025Dec 31, 202578.5×+28.8
2024Dec 31, 202449.7×+22.9
2023Dec 29, 202326.8×−148.3
2022Dec 30, 2022175.1×–

More Ocugen figures

See a number that looks wrong?